Period
recent search
Showing: 1 – 05 of 157 Regulated Information
27 July 2023
27 July 2023
Ipsen delivers solid H1 2023 results and upgrades its full-year guidance
Paris, France: 27 July 2023Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, presents today its financial results for the first half of 2023.
24 July 2023
24 July 2023
Ipsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights – effective from December 19, 2023
PARIS, FRANCE, 24 July 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) announced today that the Board of Directors of Ipsen has been informed of certain changes of the shareholders’ agreements relating to the concert of its principal shareholders.
21 July 2023
21 July 2023
Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
PARIS, FRANCE, 21 July 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Bylvay® (odevixibat) for the…
10 July 2023
10 July 2023
Ipsen – Half year statement – 2023 06 30
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF